MEDICAL POLICY

POLICY
RELATED POLICIES
POLICY GUIDELINES
DESCRIPTION
SCOPE
BENEFIT APPLICATION
RATIONALE
REFERENCES
CODING
APPENDIX
HISTORY

Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma

Number 8.01.28

Effective Date January 21, 2014

Revision Date(s) 01/13/14; 01/14/13; 01/08/12; 03/08/11; 01/12/10; 12/16/08; 12/11/07; 11/14/06; 01/10/06; 10/12/04; 03/11/03; 12/11/01; 02/01/00

Replaces N/A

Policy

Embryonal Tumors of the CNS

Autologous hematopoietic stem-cell transplantation may be considered medically necessary as consolidation therapy for previously untreated embryonal tumors of the central nervous system (CNS) that show partial or complete response to induction chemotherapy, or stable disease after induction therapy. (See Policy Guidelines)

Autologous hematopoietic stem-cell transplantation may be considered medically necessary to treat recurrent embryonal tumors of the CNS.

Tandem autologous hematopoietic stem-cell transplant is investigational to treat embryonal tumors of the CNS.

Allogeneic hematopoietic stem-cell transplantation is investigational to treat embryonal tumors of the CNS.

Ependymoma

Autologous, tandem autologous and allogeneic hematopoietic stem-cell transplant is investigational to treat ependymoma.

Related Policies

7.01.50

Placental and Umbilical Cord Blood as a Source of Stem Cells

8.01.17

Hematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome

8.01.20

Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas

8.01.21

Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms

8.01.22

Allogeneic Hematopoietic Stem-Cell Transplantation for Genetic Diseases and Acquired Anemias

8.01.23

Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer

8.01.24

Hematopoietic Stem-Cell Transplantation for Miscellaneous Solid Tumors in Adults

8.01.25

Hematopoietic Stem-Cell Transplantation for Autoimmune Diseases

8.01.26

Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia

8.01.27

Hematopoietic Stem-Cell Transplantation for Breast Cancer

8.01.29

Hematopoietic Stem-Cell Transplantation for Hodgkin Lymphoma

8.01.30

Hematopoietic Stem-Cell Transplantation for Treatment of Chronic Myelogenous Leukemia

8.01.35

Hematopoietic Stem-Cell Transplantation in the Treatment of Germ Cell Tumors

8.01.42

Hematopoietic Stem-Cell Transplantation for Primary Amyloidosis

8.01.54

Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia

8.01.511

Hematopoietic Stem-Cell Transplantation for Solid Tumors of Childhood

8.01.514

Hematopoietic Stem-Cell Support for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

8.01.520

Hematopoietic Stem-Cell Transplantation for Acute Lymphoblastic Leukemia

Policy Guidelines

In general, use of autologous hematopoietic stem-cell transplantation for previously untreated medulloblastoma has shown no survival benefit for those patients considered to be at average risk (i.e., patient age older than 3 years, without metastatic disease, and with total or near total surgical resection [<1.5 cm2 residual tumor]) when compared to conventional therapies.

Description

High-dose chemotherapy with hematopoietic stem-cell transplantation (HSCT) has been investigated as a possible therapy in pediatric patients with brain tumors, particularly in patients with disease that is considered high risk. In addition, the use of HSCT has allowed for a reduction in the dose of radiation needed to treat both average and high-risk disease, with preservation of quality of life and intellectual functioning, without compromising survival.

Background

Hematopoietic Stem -Cell Transplantation (HSCT)

HSCT refers to a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer patients who receive bone-marrow-toxic doses of cytotoxic drugs. Bone-marrow stem cells may be obtained from the transplant recipient (i.e., autologous HSCT) or from a donor (i.e., allogeneic HSCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood and placenta shortly after delivery of neonates.

Hematopoietic Stem -Cell Transplantation for Brain Tumors

Autologous HSCT allows for escalation of chemotherapy doses above those limited by myeloablation and has been tried in patients with high-risk brain tumors in an attempt to eradicate residual tumor cells and improve cure rates. The use of allogeneic HSCT for solid tumors does not rely on escalation of chemotherapy intensity and tumor reduction but rather on a graft-versus-tumor (GVT) effect. Allogeneic HSCT is not commonly used in solid tumors and may be used if an autologous source cannot be cleared of tumor or cannot be harvested.

CNS Embryonal Tumors

Classification of brain tumors is based on both histopathologic characteristics of the tumor and location in the brain. Central Nervous System (CNS) embryonal tumors are more common in children and are the most common brain tumor in childhood. CNS embryonal tumors are primarily composed of undifferentiated round cells, with divergent patterns of differentiation. It has been proposed that these tumors be merged under the term primitive neuroectodermal tumor (PNET); however, histologically similar tumors in different locations in the brain demonstrate different molecular genetic alterations. Embryonal tumors of the CNS include medulloblastoma, medulloepithelioma, supratentorial PNETs (pineoblastoma, cerebral neuroblastoma, ganglioneuroblastoma), ependymoblastoma, and atypical teratoid/rhabdoid tumor (AT/RT).

Medulloblastomas account for 20% of all childhood CNS tumors. The other types of embryonal tumors are rare by comparison. Surgical resection is the mainstay of therapy with the goal being gross total resection with adjuvant radiation therapy, as medulloblastomas are very radiosensitive. Treatment protocols are based on risk stratification, as average or high risk. The average-risk group includes children older than 3 years, without metastatic disease, and with tumors that are totally or near totally resected (<1.5 cm² of residual disease). The high-risk group includes children aged 3 years or younger, or with metastatic disease, and/or subtotal resection (>1.5 cm2 of residual disease). (1)

Current standard treatment regimens for average-risk medulloblastoma (postoperative craniospinal irradiation with boost to the posterior fossa followed by 12 months of chemotherapy) have resulted in 5- year overall survival (OS) rates of 80% or better. (1) For high-risk medulloblastoma treated with conventional doses of chemotherapy and radiotherapy, the average event-free survival (EFS) at 5 years ranges from 34 to 40% across studies.(2) Fewer than 55% of children with high-risk disease survive longer than 5 years. The treatment of newly diagnosed medulloblastoma continues to evolve, and in children younger than age 3 years, because of the concern of the deleterious effects of craniospinal radiation on the immature nervous system, therapeutic approaches have attempted to delay and sometimes avoid the use of radiation and have included trials of higher-dose chemotherapeutic regimens with autologous HSCT.

Supratentorial PNETs (sPNET) are most commonly located in the cerebral cortex and pineal region. The prognosis for these tumors is worse than for medulloblastoma, despite identical therapies. (2) After surgery, children are usually treated similarly to children with high-risk medulloblastoma. Three- to 5-year OS rates of 40 to 50% have been reported, and for patients with disseminated disease, survival rates at 5 years range from 10 to 30%.(3)

Recurrent childhood CNS embryonal tumor is not uncommon, and depending on which type of treatment the patient initially received, autologous HSCT may be an option. For patients who receive high-dose chemotherapy and autologous HSCT for recurrent embryonal tumors, objective response is 50 to 75%; however, long-term disease control is obtained in fewer than 30% of patients and is primarily seen in patients in first relapse with localized disease at the time of relapse. (3)

Ependymoma

Ependymoma is a neuroepithelial tumor that arises from the ependymal lining cell of the ventricles and is, therefore, usually contiguous with the ventricular system. An ependymoma tumor typically arises intracranially in children, while in adults a spinal cord location is more common. Ependymomas have access to the cerebrospinal fluid and may spread throughout the entire neuroaxis. Ependymomas are distinct from ependymoblastomas due to their more mature histologic differentiation. Initial treatment of ependymoma consists of maximal surgical resection followed by radiotherapy. Chemotherapy usually does not play a role in the initial treatment of ependymoma. However, disease relapse is common, typically occurring at the site of origin. Treatment of recurrence is problematic; further surgical resection or radiation therapy is usually not possible. Given the poor response to conventional-dose chemotherapy, high-dose chemotherapy with autologous HSCT has been investigated as a possible salvage therapy.

Note: Other CNS tumors include astrocytoma, oligodendroglioma, and glioblastoma multiforme. However, these tumors arise from glial cells and not neuroepithelial cells. These tumors are considered in a separate policy. (See Related Policies)

Note: Due to their neuroepithelial origin, peripheral neuroblastoma and Ewing’s sarcoma may be considered PNETs. However, these peripheral tumors are considered in a separate policy. (See Related Policies)

Scope

Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply.

Benefit Application

The following considerations may supersede this policy:

  • State mandates requiring coverage for autologous bone marrow transplantation offered as part of clinical trials of autologous bone marrow transplantation approved by the National Institutes of Health (NIH).

Rationale

This policy was originally created in December 1998 and was updated regularly with searches of the MEDLINE database. The most recent literature search was performed through October 8, 2013. Following is the summary of the key literature to date.

CNS Embryonal Tumors

Newly diagnosed

Chintagumpala et al. reviewed event-free survival (EFS) of 16 patients with newly diagnosed supratentorial primitive neuroectodermal tumor (sPNET) treated with risk-adapted craniospinal irradiation and subsequent high-dose chemotherapy with autologous hematopoietic stem-cell transplantation (HSCT) between 1996 and 2003. (4) Eight patients were considered at average risk, and 8 were at high risk (defined as the presence of residual tumor larger than 1.5 cm2 or disseminated disease in the neuroaxis). Median age at diagnosis was 7.9 years (range, 3-21 years). Seven patients had pineal primitive neuroectodermal tumor (PNET). After a median follow-up of 5.4 years, 12 patients were alive. Five-year EFS and overall survival (OS) for the patients with average -risk disease were 75% 17%) and 88% 13%), respectively, and for the high-risk patients 60% 19%) and 58% 19%), respectively. No treatment -related toxicity deaths were reported. The authors concluded that high-dose chemotherapy with stem-cell support after risk-adapted craniospinal irradiation allows for a reduction in the dose of radiation needed to treat nonmetastatic, average-risk sPNET, without compromising EFS.

Fangusaro et al. reported outcomes for 43 children with newly diagnosed sPNET treated prospectively in 2 serial studies (Head Start 1 [HS1] and Head Start 2 [HS2]) between 1991 and 2002 with intensified induction chemotherapy followed by myeloablative chemotherapy and autologous HSCT.(2) There were no statistical differences between HS1 and HS2 patient demographics. After maximal surgical resection, patients underwent induction chemotherapy. If, after induction, the disease remained stable or there was partial or complete response, patients underwent myeloablative chemotherapy with autologous HSCT (n=32). Patients with progressive disease at the end of induction were not eligible for consolidation. Five -year EFS and OS were 39% (95% confidence interval [CI], 24 to 53%) and 49% (95% CI: 33 to 62%), respectively. Patients with nonpineal tumors did significantly better than patients with pineal PNETs (2- year and 5-year EFS of 57% vs 23% and 48% vs 15%, respectively, and 2-year and 5-year OS of 70% vs 31% and 60% vs 23%, respectively). Sixty percent of survivors were alive without exposure to radiation therapy.

Dhall et al. reported outcomes for children younger than 3 years of age at diagnosis of nonmetastatic medulloblastoma, after being treated with 5 cycles of induction chemotherapy and subsequent myeloablative chemotherapy and autologous HSCT. (5) Twenty of 21 children enrolled completed induction chemotherapy, of whom 14 had a gross total surgical resection and 13 remained free of disease at the completion of induction chemotherapy. Of 7 patients with residual disease at the beginning of induction, all achieved a complete radiographic response to induction chemotherapy. Of the 20 patients who received consolidation chemotherapy, 18 remained free of disease at the end of consolidation. In patients with gross total tumor resection, 5-year EFS and OS were 64% 13) and 79% 11), respectively, and for patients with residual tumor, 29% 17) and 57% 19), respectively. There were 4 treatment -related deaths. The need for craniospinal irradiation was eliminated in 52% of the patients, and 71% of survivors avoided irradiation completely, with preservation of quality of life and intellectual functioning.

Gajjar et al. reported the results of risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and autologous HSCT in 134 children with newly diagnosed medulloblastoma. (6) After tumor resection, patients were classified as having average-risk disease (n=86), defined as equal to or less than 1.5 cm2 residual tumor and no metastatic disease, or high-risk disease (n=48), defined as greater than 1.5 cm2 residual disease or metastatic disease localized to the neuroaxis. A total of 119 children completed the planned protocol. Five -year OS was 85% (95% CI: 75 to 94%) among the average-risk cases and 70% (95% CI: 54 to 84%) in the high-risk patients. Five -year EFS was 83% (95% CI: 73 to 93%) and 70% (95% CI: 55–85) for average- and high-risk patients, respectively. No treatment-related deaths were reported.

Lee and colleagues retrospectively reviewed the medical records of 13 patients diagnosed with atypical teratoid/rhabdoid tumor (AT/RT) who were treated at their institute at Seoul National Children’s University Hospital (Korea). (7) The median age was 12 months (range: 3–67 months), and 7 patients were younger than 1-year old at the time of diagnosis. Three patients (23%) underwent high-dose chemotherapy and autologous HSCT. The authors assessed the impact on OS in these 3 patients, as compared to the remaining 10 patients undergoing other chemotherapy regimens. No statistical difference in OS was observed between these 2 groups (p=0.36); however, the median survival was reported to be higher in the HSCT group (15 months) compared to the non-HSCT group (9 months). (7)

National Cancer Institute (NCI) Clinical Trial Database (PDQ®)

  • A Phase III study of combination chemotherapy, radiation therapy, and an autologous peripheral blood stem-cell transplant in treating young patients with AT/RT (NCT00653068, COG-ACNS0333) is active. The primary purpose of this multi-center study (being undertaken in 88 trial sites across the U.S., Australia, and Canada) is to determine the EFS and OS of children (birth to 21 years of age) with AT/RT treated with surgery, high-dose chemotherapy combined with HSCT, and radiation therapy. Expected enrollment is 70 patients, with an estimated trial completion date of April 2014.
  • A Phase III study of radiation therapy and combination chemotherapy followed by autologous stem-cell transplant in patients with newly diagnosed medulloblastoma, supratentorial primitive neuroectodermal tumor, or atypical teratoid rhabdoid tumor (NCT00085202, SJCRH-SJMB03) is active. The purpose of the study is to compare two different regimens of radiation therapy when given together with chemotherapy and autologous stem-cell transplant. Projected accrual is 413 patients, and estimated date of study completion is September 2018.
  • A Phase III pilot study of induction chemotherapy followed by consolidation myeloablative chemotherapy comprising thiotepa and carboplatin with or without etoposide followed by autologous hematopoietic stem -cell rescue in pediatric patients with previously untreated malignant brain tumors (NCT00392886, CHLA-HEAD-START-III) is closed. The study compares two alternative induction regimens prior to myeloablative chemotherapy and stem-cell rescue. Expected enrollment was 120 patients, with an estimated trial completion date in December 2010. The publication date of this study is presently unknown.
  • A Phase III randomized study of intensive induction chemotherapy comprising vincristine, etoposide, cyclophosphamide, and cisplatin with or without high-dose methotrexate and leucovorin followed by consolidation chemotherapy comprising carboplatin and thiotepa and peripheral blood stem-cell rescue in pediatric patients with newly diagnosed supratentorial primitive neuroectodermal tumors or high-risk medulloblastoma (NCT00336024, COGACNS0334) is active. The study was intended to compare the response rate of induction therapy with or without methotrexate and leucovorin. Expected enrollment is 96 patients, with an estimated trial completion date of September 2018.

Recurrent

Raghuram et al. performed a systematic review of the literature regarding the outcome of patients with relapsed sPNET treated with high-dose chemotherapy and autologous HSCT. (8) Eleven observational studies published before 2010 met their inclusion criteria; 4 of these were prospective case-series. The 11 studies consisted of 46 patients diagnosed with relapsed sPNET or pineoblastoma who received autologous HSCT for treatment of relapse. Of those, 15 patients were children younger than 3 years of age, and 15 were pineoblastomas. With a median follow-up of 40 months (range 3-123 months) 15 patients were reported alive. Thirteen patients (of 15 survivors) did not receive craniospinal irradiation. The 12-month OS rate of the cohort was 44.2±7.5 months. Twelve-month OS for children younger than 36 months was 66.7±12.2 months, while for older children, 12-month OS was 27.8±10.6 (p=0.003). Twelve-month OS was 20.0±10.3 for those patients with pineoblastoma versus 54.6±9.0 for those with non-pineal sPNETs (p<0.001). Cox regression analysis revealed pineal location as the only independent adverse prognostic factor. (8) Based on these pooled results, high-dose chemotherapy with HSCT might lead to survival primarily in younger children with relapsed sPNET, even in the absence of concomitant use of radiotherapy, whereas the outcome in older children and/or in a pineal location is poor with this modality.

Dunkel et al. report an expanded series with longer follow-up using autologous HSCT for previously irradiated recurrent medulloblastoma. (9, 10) Twenty-five patients were treated between 1990 and 1999 and included 18 males and 7 females with a median age at diagnosis of 11.5 years (range: 4.2-35.5 years). Median age at the time of HSCT was 13.8 years (range, 7.6-44.7 years). All patients had previously received postoperative external -beam radiation with (n=15) or without (n=10) chemotherapy. The median time from diagnosis to disease relapse or progression was 29.8 months (range, 5.3-114.7 months). Stage at the time of relapse was M0 n=6, M1 n=1, M2 n=8, M3 n=10 (M0=no evidence of subarachnoid or hematogenous metastasis, M1=tumor cells found in cerebrospinal fluid, M2=intracranial tumor beyond primary site, M3=gross nodular seeding in spinal subarachnoid space). High-dose chemotherapy prior to HSCT consisted of carboplatin, thiotepa, and etoposide. Treatment-related mortality was 12% within 30 days of transplant. Tumor recurred in 16 patients at a median of 8.5 months after HSCT (range, 2.3-58.5 months). Median OS was 26.8 months (95% CI: 11.9 to 51.1 months) and EFS and OS at 10 years post-HSCT was 24% for both (95% CI: 9.8 to 41.7%). The authors concluded that this retrieval strategy provides long-term EFS for some patients with previously irradiated recurrent medulloblastoma.

In the earlier publication, Dunkel et al. reported the outcomes of 23 patients with recurrent medulloblastoma treated with high-dose carboplatin, thiotepa, and etoposide. (10) Seven patients were event-free survivors at a median of 54 months, with OS estimated at 46% at 36 months. HSCT was expected to be most effective with minimal disease burden. Thus, Dunkel et al. suggested increased surveillance for recurrence or aggressive surgical debulking at the time of recurrence. The authors also acknowledged the potential for effects of patient selection bias on their results, since not all patients eligible for the protocol were enrolled.

Grodman et al. reported outcomes of 8 patients with relapsed medulloblastoma with metastasis (n=7) and relapsed germinoma (n=1) who received dose-intensive chemotherapy with autologous HSCT. (11) Mean age was 12.9 years (range, 5-27.8 years). Mean survival post-transplant was 4.8 years (range, 8–160+ months). The 2-year and 5-year OS rates were 75% and 50%, respectively.

Gill et al. reported outcomes for 23 adult patients (18 years or older) treated for recurrent embryonal central nervous system (CNS) tumors between 1976 and 2004, comparing high-dose chemotherapy with autologous HSCT (n=10) with a historic control group of patients treated with conventional-dose chemotherapy (n=13). (12) In the HSCT group, 6 patients received tandem autologous transplants. Autologous HSCT was associated with increased survival (p=0.044) and a longer time to disease progression (TTP) (p=0.028). Median TTP for the conventional versus HSCT group was 0.58 years and 1.25 years, respectively. Median survival was 2.00 years and 3.47 years, respectively. There were no long-term survivors in the conventional chemotherapy group. With a median follow-up of 2.9 years, 5 of the HSCT patients were alive, 4 without disease progression. In a Comparison of outcomes between the patients who received a single versus tandem transplant, there was improvement in TTP favoring tandem transplant (p=0.046), but no difference in survival was observed (p=0.132).

Tandem Transplant

In 2013, Sung et al. reported the results of reduced-dose craniospinal radiotherapy followed by tandem double high-dose chemotherapy with autologous HSCT in 20 children older than 3 years of age with high-risk medulloblastoma (17 with metastatic disease and 3having a postoperative residual tumor >1.5 cm2 without metastasis). (13) The tumor relapsed/progressed in 4 patients, and 2 patients died of toxicity during the second transplant. Fourteen (70%) patients remained event-free at a median follow-up of 46 months (range, 23-82 months) from diagnosis. Late adverse effects evaluated at a median of 36 months (range, 12-68 months) after tandem HSCT included hypothyroidism, growth hormone deficiency, sex hormone deficiency, hearing loss, and renal tubulopathy. (13)

In 2013, Friedrich et al. reported the results of double tandem high-dose chemotherapy with autologous HSCT in 3 children younger than 4 years of age with metastatic sPNET. (14) These patients also received preventive craniospinal radiotherapy; they had residual disease before HSCT, but no evidence of disease after transplant (survival ranging from 2 to 10 years). (14)

Park et al. reported the results of tandem double high-dose chemotherapy with autologous HSCT in 6 children younger than 3 years of age with newly diagnosed AT/RT. (15) No treatment-related death occurred during the tandem procedure, and 5 (of 6) patients were alive at a median follow-up of 13 months (range, 7-64) from first HSCT. Although 3 patients remained progression-free after tandem HSCT, the effectiveness of this modality is unclear because all survivors received radiotherapy, as well as tandem HSCT. (15)

Sung et al. reported the results of a single or tandem double high-dose chemotherapy with autologous HSCT in 25 children with newly diagnosed high-risk or relapsed medulloblastoma or PNET following surgical resection. (16) Three-year EFS for patients in complete remission (CR) or partial remission (PR) and less than PR at first high-dose chemotherapy was 67% or 16.7%, respectively. For 19 cases in CR or PR at first high-dose chemotherapy, 3-year EFS was 89% in the tandem double group and 44% in the single high-dose chemotherapy group, respectively. Four treatment-related deaths occurred, and in 4 of 8 young children, craniospinal radiotherapy was successfully withheld without relapse.

Allogeneic Transplant

The use of allogeneic HSCT for CNS embryonal tumors consists of rare case reports with mixed results. (15-17-19)

National Cancer Institute (NCI) Clinical Trial Database (PDQ®)

No Phase III randomized trials using HSCT for recurrent embryonal CNS tumors are identified.

Ependymoma

Literature regarding autologous HSCT for the treatment of ependymoma primarily consists of small case series. Sung et al. reported the results of tandem double high-dose chemotherapy with autologous HSCT in 5 children younger than 3 years of age with newly diagnosed anaplastic ependymoma. (20) All patients were alive at median follow-up of 45 months (range, 31-62) from diagnosis, although tumor progressed at the primary site in one patient. No significant endocrine dysfunction occurred except for hypothyroidism in one patient, and one patient had significant neurologic injury from primary surgical treatment. (20) The results of this very small case series indicate that treatment with tandem HSCT is feasible in very young children with anaplastic ependymoma and that this strategy might also be a possible option to improve survival in these patients without unacceptable long-term toxicity. Further studies with larger patient cohorts are needed to confirm these results.

Mason et al. reported on a case series of 15 patients with recurrent ependymoma. (21) Five patients died of treatment-related toxicities, 8 died from progressive disease, and 1 died of unrelated causes. After 25 months, 1 patient remains alive but with tumor recurrence. The authors concluded that their high-dose regimen of thiotepa and etoposide was not an effective treatment of ependymoma. Grill et al. similarly reported a disappointing experience in 16 children treated with a thiotepa-based high-dose regimen. (22)

A small series reported 5-year EFS of 12% 6%) and OS of 38% 10%) among 29 children younger than 10 years of age who received autologous HSCT following intensive induction chemotherapy to treat newly diagnosed ependymoma. (23) Importantly, radiation-free survival was only 8% 5%) in these cases. The results of these series, although limited in size, further suggest HSCT is not superior to other previously reported chemotherapeutic approaches.

National Cancer Institute (NCI) Clinical Trial Database (PDQ®)

A Phase III pilot study of induction chemotherapy followed by consolidation myeloablative chemotherapy comprising thiotepa and carboplatin with or without etoposide followed by autologous hematopoietic stem -cell rescue in pediatric patients with previously untreated malignant brain tumors, including ependymomas (NCT00392886; CHLA-HEAD-START-III) is closed. The study compares 2 alternative induction regimens prior to myeloablative chemotherapy and stem-cell rescue. Expected enrollment was 120 patients, with an estimated trial completion date in December 2010. The publication date of this study is presently unknown.

Summary

Data from single-arm studies using high-dose chemotherapy with autologous hematopoietic stem-cell transplantation (HSCT) to treat newly diagnosed central nervous system (CNS) embryonal tumors have shown an improved survival benefit (both event-free and overall), particularly in patients with disease that is considered high-risk. In addition, the use of autologous HSCT has allowed for a reduction in the dose of radiation needed to treat both average and high-risk disease, with preservation of quality of life and intellectual functioning, without compromising survival.

Data from single-arm studies using autologous HSCT to treat recurrent CNS embryonal tumors have shown improved survival benefit for some patients. The results from a 2012 systematic review of observational studies in patients with relapsed supratentorial primitive neuroectodermal tumor (sPNET) suggest that a sub-group of infants with chemo-sensitive disease might benefit from autologous HSCT, achieving survival without the use of radiation therapy, whereas the outcome in older children and/or in pineal location is poor with this modality.

More data on the use of tandem and allogeneic transplants for CNS embryonal tumors are needed.

The use of HSCT for ependymoma has not shown a survival benefit compared to the use of conventional approaches, and the policy statement regarding ependymoma remains investigational.

Practice Guidelines and Position Statements

National Comprehensive Cancer Network (NCCN) Practice Guidelines 2013

NCCN guidelines on treating CNS tumors do not address the use of autologous HSCT in treating ependymomas. For medulloblastoma and supratentorial PNET, autologous HSCT for recurrent disease with maximum safe resection is a category 2A recommendation.(24)

References

  1. Mueller S, Chang S. Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics 2009; 6(3):570-86.
  2. Fangusaro J, Finlay J, Sposto R et al. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience. Pediatr Blood Cancer 2008; 50(2):312-18.
  3. National Cancer Institute Physician Data Query (PDQ®). Childhood Central Nervous System Embryonal Tumors (last modified August 1, 2013). Available online at: http://www.cancer.gov/cancertopics/pdq/treatment/childCNSembryonal/healthprofessional. Last accessed October, 2013.
  4. Chintagumpala M, Hassall T, Palmer S et al. A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol 2009; 11(1):33-40.
  5. Dhall G, Grodman H, Ji L et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols. Pediatr Blood Cancer 2008; 50(6):1169-75.
  6. Gajjar A, Chintagumpala M, Ashley D et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006; 7(10):813-20.
  7. Lee JY, Kim IK, Phi JH et al. Atypical teratoid/rhabdoid tumors: the need for more active therapeutic measures in younger patients. J Neurooncol 2012; 107(2):413-9.
  8. Raghuram CP, Moreno L, Zacharoulis S. Is there a role for high dose chemotherapy with hematopoietic stem cell rescue in patients with relapsed supratentorial PNET? J Neurooncol 2012; 106(3):441-7.
  9. Dunkel I, Gardner S, Garvin J et al. High-dose carboplatin, thiotepa, and etoposide with autologous stemcell rescue for patients with previously irradiated recurrent medulloblastoma. Neuro Oncol 2010; 12(3):297-303.
  10. Dunkel IJ, Boyett JM, Yates A et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem -cell rescue for patients with recurrent medulloblastoma. Children’s Cancer Group. J Clin Oncol 1998; 16(1):222-8.
  11. Grodman H, Wolfe L, Kretschmar C. Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue. Pediatr Blood Cancer 2009; 53(1):33-6.
  12. Gill P, Litzow M, Buckner J et al. High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. Cancer 2008; 112(8):1805-11.
  13. Sung KW, Lim do H, Son MH et al. Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma. Neuro Oncol 2013; 15(3):352-9.
  14. Friedrich C, von Bueren AO, von Hoff K et al. Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy. Neuro Oncol 2013; 15(2):224-34.
  15. Park ES, Sung KW, Baek HJ et al. Tandem high-dose chemotherapy and autologous stem cell transplantation in young children with atypical teratoid/rhabdoid tumor of the central nervous system. Journal of Korean medical science 2012; 27(2):135-40.
  16. Sung KW, Yoo KH, Cho EJ et al. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer 2007; 48(4):408-15.
  17. Lundberg JH, Weissman DE, Beatty PA et al. Treatment of recurrent metastatic medulloblastoma with intensive chemotherapy and allogeneic bone marrow transplantation. J Neurooncol 1992; 13(2):151–5.
  18. Matsuda Y, Hara J, Osugi Y et al. Allogeneic peripheral stemcell transplantation using positively selected CD34+ cells from HLA-mismatched donors. Bone Marrow transplant 1998; 21(4):355–60.
  19. Secondino S, Pedrazzoli P, Schiavetto I et al. Antitumor effect of allogeneic hematopoietic SCT in metastatic medulloblastoma. Bone Marrow Transplant 2008; 42(2):131-3.
  20. Sung KW, Lim do H, Lee SH et al. Tandem high-dose chemotherapy and autologous stem cell transplantation for anaplastic ependymoma in children younger than 3 years of age. J Neurooncol 2012; 107(2):335-42.
  21. Mason WP, Goldman S, Yates AJ et al. Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma: a report of the Children’s Cancer Group. J Neuro-Oncol 1998; 37(2):135-43.
  22. Grill J, Kalifa C, Doz F et al. A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A phase-II study. Pediatr Neurosurg 1996; 25(1):7-12.
  23. Zacharoulis S, Levy A, Chi SN et al. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 2007; 49(1):34-40.
  24. National Comprehensive Cancer Network Practice Guidelines in Oncology. Central Nervous System Cancers (v2). 2013. Available online at: http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf. Last accessed December 12, 2013October, 2013.Blue Cross and Blue Shield Association. Hematopoietic Stem-Cell Transplantation for CNS Embryonal Tumors and Ependymoma. Medical Policy Reference Manual, Policy 8.01.28, 2012.

Coding

Codes

Number

Description

CPT

38206

Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection, autologous

 

38207

Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage

 

38208

Transplant preparation of hematopoietic progenitor cells; Thawing of previously frozen harvest, without washing

 

38209

Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest, with washing

 

38210

Specific cell depletion within harvest, T cell depletion

 

38211

Tumor cell depletion

 

38213

Platelet depletion

 

38214

Plasma (volume) depletion

 

38215

Cell concentration in plasma, mononuclear, or buffy coat layer

 

38232

Bone marrow harvesting for transplantation; autologous

 

86825

Human leukocyte antigen (HLA) crossmatch, non-cytotoxic (e.g., using flow cytometry); first serum sample or dilution

 

86826

Human leukocyte antigen (HLA) crossmatch, non-cytotoxic (e.g., using flow cytometry); each additional serum sample or sample dilution (List separately in addition to primary procedure)

 

38240

Bone marrow or blood-derived peripheral stem-cell transplantation; allogeneic

 

38241

autologous

ICD-9 Procedure

41.01

Autologous bone marrow transplant without purging

 

41.02

Allogeneic bone marrow transplant with purging

 

41.03

Allogeneic bone marrow transplant without purging

 

41.04

Autologous hematopoietic stem cell transplant without purging

 

41.05

Allogeneic hematopoietic stem cell transplant without purging

 

41.06

Cord blood stem cell transplant

 

41.07

Autologous hematopoietic stem-cell transplant with purging

 

41.09

Autologous bone marrow transplant with purging

 

41.91

Aspiration of bone marrow from donor for transplant

 

99.79

Other therapeutic apheresis (includes harvest of stem cells)

ICD-9 Diagnosis

191.0 - 191.9

Malignant neoplasm of brain, cerebrum, except lobes and ventricles

 

191.1

Frontal lobe

 

191.2

Temporal lobe

 

191.3

Parietal lobe

 

191.4

Occipital lobe

 

191.5

Ventricles

 

191.6

Cerebellum NOS

 

191.7

Brain stem

 

191.8

Other parts of brain

 

191.9

Brain, unspecified

HCPCS

S2150

Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications including pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and post-transplant care in the global definition

ICD-10-CM
(effective 10/01/14)

C71.0 - C71.9

Malignant neoplasm of brain

ICD-10-PCS
(effective 10/01/14)

30243G0, 30243X0, 30243Y0

Percutaneous transfusion, central vein, bone marrow or stem cells, autologous, code list

 

30243G1, 30243X1, 30243Y1

Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list

 

07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ

Surgical, lymphatic and hemic systems, extraction, bone marrow, code list

Type of Service

Therapy

 

Place of Service

Inpatient
Outpatient

 

Appendix

N/A

History

Date

Reason

02/01/00

Add to Therapy Section - New Policy — replaces 8.01.15, original master policy on high-dose chemotherapy for miscellaneous malignancies. However, policy statement is unchanged.

12/11/01

Replace Policy - Policy references updated.

03/11/03

Replace Policy - Policy updated and references added; no change in policy statement.

10/12/04

Replace Policy - Policy updated with literature review; policy statement unchanged (text updated for clarification only). Approved by OAP 10/29/04, no need to go back to MPC.

01/10/06

Replace Policy - Policy updated with literature review; no change to policy statement. Reviewed by OAP 10/27/05.

06/02/06

Disclaimer and Scope update - No other changes

11/14/06

Replace Policy - Policy reviewed and recommended by OAP October 26, 2006; no changes to policy statement.

12/11/07

Replace Policy - Policy updated with literature review. Policy statement added to indicate that multi-cycle high-dose chemotherapy (with or without associated radiotherapy) and autologous stem-cell support (i.e., tandem transplants) as investigational. Policy reviewed and recommended by OAP November 15, 2007.

05/13/08

Cross Reference Update - No other changes

12/16/08

Replace Policy - Policy updated with literature search; no change to the policy statement. References added. Reviewed and recommended by OAP, August 21, 2008.

01/13/09

Code Updates - Code added, J8705; effective 1/1/09.

01/12/10

Replace Policy - Policy extensively revised with literature search; policy title changed to remove “high-dose chemotherapy” and to change PNET to embryonal tumors. Policy statement changed regarding autologous consolidation therapy in patients with previously untreated embryonal tumors showing complete or partial response to, or stable disease after, induction therapy; now considered medically necessary. Other policy statements reworded and separated to address ependymoma and embryonal CNS tumors specifically; however, the intent of the statements remains the same. References added.

02/09/10

Code Update - New 2010 codes added.

03/08/11

Replace Policy - Policy updated with literature search through October 2010; references 7, 12-14 added. No change to policy statements.

05/12/11

Reviewed by OAP - No changes recommended to the policy.

01/06/12

Replace Policy – Policy updated with literature search. No references added; no change in policy statements. ICD-10 codes added.

01/24/12

Code 38232 added.

02/10/12

The CPT code 38204 was removed from the policy.

06/20/12

Minor update: Related Policies updated; 8.01.17 replaced 8.01.507 effective June 12, 2012.

07/30/12

Related Policy title updates to: 8.01.17, 8.01.22, 8.01.31, 8.01.35 and 8.01.520. Deleted 8.01.38 as it was archived.

10/08/12

Update Coding Section – ICD-10 codes are now effective 10/01/2014.

01/29/13

Replace policy. Policy updated with literature search. References 7, 8, 13 and 18 added; no change in policy statements. Removed CPT codes 38220 and 38221; they do not apply to this policy. Change title to Related Policy 8.01.21.

03/20/13

The following codes were removed from the policy, as they were not suspending and just informational: HCPCS J9000-J9999 and Q0083 – Q0085.

09/30/13

Update Related Policies. Change policy title to 8.01.31.

10/18/13

Update Related Policies. Change title to policy 8.01.17.

01/21/14

Replace policy. Policy updated with literature search through October 8, 2013. References 13 and 14 added, references 3 and 24 updated; no change in policy statements. Remove CPT code 38230; it does not apply to this policy.


Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA).
©2014 Premera All Rights Reserved.